RNA editing oligonucleotide selected for AATD treatment
Korro Bio, a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of alpha-1 antitrypsin deficiency (AATD). KRRO-110 is an RNA editing oligonucleotide delivered to liver cells… Read More